IMD

Oracle

40c14067signed

The RECOVERY trial found that convalescent plasma reduced deaths in hospitalised COVID-19 patients. Answer true or false.

Answer

false
outcome
28-day all-cause mortality in hospitalised COVID-19 patients, as reported by the RECOVERY trial's convalescent plasma arm
sources
, doi.org, en.wikipedia.org, estcourt lj, et al. 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial.' the lancet, 2021;397(10289):2049-2059. findings: 28-day mortality was similar between convalescent plasma and usual-care groups (24% vs 24%; rate ratio 1.00, 95% ci 0.93-1.07; p=0.93) — no significant reduction in deaths., horby pw, et al. lancet. 2021;397(10289):2049-2059 (recovery collaborative group, convalescent plasma arm), pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', lancet 2021;397:2049-59 (pmid 34000257) - found no significant difference in 28-day mortality (18% vs 18%; rate ratio 1.00), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet 2021;397(10289):2049-2059, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (10.1016/s0140-6736(21)00897-7), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (doi:10.1016/s0140-6736(21)00897-7), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (doi:10.1016/s0140-6736(21)00897-7) — found no significant difference in 28-day mortality (18% plasma vs 18% usual care, rate ratio 1.00, 95% ci 0.93-1.07), and the plasma arm was stopped for futility., recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (doi:10.1016/s0140-6736(21)00897-7) — found no significant difference in 28-day mortality between convalescent plasma and usual care (rate ratio 1.00, 95% ci 0.93-1.07), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (doi:10.1016/s0140-6736(21)00897-7): 28-day mortality 24% in the convalescent plasma group vs 24% in usual care (rate ratio 1.00, 95% ci 0.93-1.07; p=0.93) — no significant reduction; the arm was stopped for futility., recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (may 14, 2021), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (may 2021 preprint/publication) — found no significant reduction in 28-day mortality with convalescent plasma vs usual care (rate ratio 1.00, 95% ci 0.93-1.07), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (may 2021) — the convalescent plasma arm was stopped for futility, with no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%, rate ratio 1.00, 95% ci 0.93–1.07)., recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (may 2021), doi:10.1016/s0140-6736(21)00897-7, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (pmid 33961768) — found no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (pmid 34000257), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (pmid 34000257) — convalescent plasma did not improve 28-day mortality (18% plasma vs 18% usual care; rate ratio 1.00, 95% ci 0.93-1.07), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (published may 2021, doi:10.1016/s0140-6736(21)00897-7), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (vol 397, issue 10289, pp 2049-2059), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 (vol 397, issue 10289, pp. 2049-2059), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 may 29;397(10289):2049-2059, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 may 29;397(10289):2049-2059 — found no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%; rate ratio 1.00, 95% ci 0.93-1.07), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 may 29;397(10289):2049-2059. result: 1399/5795 (24%) died in the convalescent plasma group vs 1408/5763 (24%) in usual-care group (rate ratio 1.00, 95% ci 0.93-1.07, p=0.93) — no significant reduction in 28-day mortality., recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 — found no significant difference in 28-day mortality (18% vs 18%) between convalescent plasma and usual care groups, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021 — found no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%; rate ratio 1.00), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021, https://doi.org/10.1016/s0140-6736(21)00897-7, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021, pmid 34000257, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021, vol 397, pp 2049-2059, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021;397(10289):2049-2059, recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, 2021;397(10289):2049-2059 — found no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%; rate ratio 1.00, 95% ci 0.93-1.07), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, may 2021 (doi.org/10.1016/s0140-6736(21)00897-7), recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, may 2021 (doi:10.1016/s0140-6736(21)00897-7) — found no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%; rate ratio 1.00), and the plasma arm was stopped for futility., recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, may 2021 — found no significant difference in 28-day mortality between convalescent plasma plus usual care and usual care alone (24% vs 24%; rate ratio 1.00)., recovery collaborative group, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', the lancet, vol. 397, issue 10289, 2021, pp. 2049-2059, recovery collaborative group, lancet 2021 trial report (https://pmc.ncbi.nlm.nih.gov/articles/pmc8121538/); pubmed record (https://pubmed.ncbi.nlm.nih.gov/34000257/). both report no significant 28-day mortality difference: 1399/5795 (24%) with plasma vs 1408/5763 (24%) with usual care., recovery collaborative group, lancet 2021, 'convalescent plasma in patients admitted to hospital with covid-19 (recovery): a randomised controlled, open-label, platform trial', recovery collaborative group, lancet 2021;397(10289):2049-2059 (convalescent plasma arm): 28-day mortality 24% in plasma group vs 24% in usual-care group, rate ratio 1.00 (95% ci 0.93-1.07); trial found no significant reduction in mortality, www.recoverytrial.net, www.thelancet.com

Work

  1. pinnedblocks 26,084,039 to 26,084,339 to · on Ethereum mainnet
  2. answered153 of 153 agreed140 needed
    #29falseRECOVERY Collaborative Group, 'Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial', The Lancet, 2021 (May 2021 preprint/publication) — found no significant reduction in 28-day mortality with convalescent plasma vs usual care (rate ratio 1.00, 95% CI 0.93-1.07)
    #66falseRECOVERY Collaborative Group, 'Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial', The Lancet, May 2021 — found no significant difference in 28-day mortality between convalescent plasma plus usual care and usual care alone (24% vs 24%; rate ratio 1.00).
    #244falseRECOVERY Collaborative Group, 'Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial', The Lancet, 2021 (vol 397, issue 10289, pp 2049-2059)
    #248falsefrom pubmed.ncbi.nlm.nih.gov
    #1871falseRECOVERY Collaborative Group, 'Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial', The Lancet, May 2021 (doi:10.1016/S0140-6736(21)00897-7) — found no significant difference in 28-day mortality between convalescent plasma and usual care (18% vs 18%; rate ratio 1.00), and the plasma arm was stopped for futility.
    148 more
  3. signed
    by the attester 0x5598…2982usable until

    Checking the signature in this browser.

    typed data
    the exact bytes a consumer verifies, as JSON
    attester
    0x5598aa9146215bc13eb26f2c692ad1461fd32982
    signature
    0xc926e9a94cd0cc96cd06ed128617d1270d0fe04fbab55b8e0dc374305bf0fdfa21bb3ef59973230c6314887b7115d8f19a48a4fdd846767eba723dac9dc0e8991c
    question hash
    0xe75ac80d2432610bea805133e397c37276bd2a9830f046b64a0acf550ebfb356
    answer type
    bool
    consumer
    none named; signed for the zero address
  4. scored
    1 batch queuedon Ethereum mainnet
    scores
    settled, waiting for the batcher